Loss of heterozygosity: A potential tool in management of oral premalignant lesions?

Journal of Oral Pathology and Medicine

Volumn 30, Issue 9, 2001, Pages 513-520

  Zhang, L ^a   Rosin, M P ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Cancer recurrence; Loss of heterozygosity (LOH); Oral premalignancy; Oral squamous cell carcinoma; Risk prediction

Indexed keywords

MICROSATELLITE DNA;

CANCER STAGING; GENETICS; HETEROZYGOSITY LOSS; HUMAN; LEUKOPLAKIA; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKOPLAKIA, ORAL; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MOUTH NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT;

EID: 0034784682     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0714.2001.300901.x     Document Type: Review

References (72)

1. A proposal for a classification and staging system for oral leukoplakia: A preliminary study
2. Oral white lesions with special reference to precancerous and tobacco-related lesions: Conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994
3. Malignant transformation of leukoplakia
4. Malignant transformation of leukoplakia
5. Oral precancer: Preventive and medical approaches to management
6. How many mutations are required for tumorigenesis? Implications from human cancer data
7. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis
8. P53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells
9. ras gene mutations in oral cancer in eastern India
10. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck
11. Molecular lesions in human cancer: The Indian scene
12. C-Ha-ras oncogene in oral leukoplakia tissues
13. Aberrations of erbB-1 and erbB-2 oncogenes in non-dysplastic leukoplakias of the oral cavity
14. Visualization of INT2 and HST1 amplification in oral squamous cell carcinoma
15. Point mutations in the H-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases
16. TGF-alpha and oral carcinogenesis
17. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer
18. Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis
19. Cyclin D1 overexpression in primary hypopharyngeal carcinomas
20. Expression of c-erbB2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female tract
21. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment
22. The loss of heterozygosity in retinoblastoma and p53 suppressor genes as a prognostic indicator for head and neck cancer
23. High frequency of p16 inactivation in head and neck squamous cell carcinoma
24. An allelotype of squamous carcinoma of the head and neck using microsatellite markers
25. Human cancer syndromes: Clues to the origin and nature of cancer
26. Genetic progression model for head and neck cancer: Implications for field cancerization
27. Molecular analysis of oral lichen planus: Is this a premalignant lesion?
28. High frequency of allelic loss in dysplastic lichenoid lesions
29. Allelotype of squamous cell carcinoma of the head and neck: Fractional allele loss correlates with survival
30. The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer
31. Three discrete regions of deletion at 3p in head and neck cancers
32. A common region of allelic loss on chromosome region 3p25.3-26.3 in nasopharyngeal carcinoma
33. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer
34. Deletion of chromosome 3p is an early event in malignant progression of cervical cancer
35. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines
36. The FHIT gene in oral squamous cell carcinoma: Allelic imbalance is frequent but cDNA aberrations are uncommon
37. Abnormalities of the FHIT gene in human oral carcinogenesis
38. Tumor suppressor genes: Does FHIT fit?
39. A genetic model for colorectal tumorigenesis
40. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia
41. Can molecular assessment improve classification of head and neck premalignancy?
42. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization
43. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer
44. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients
45. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
46. From epithelial dysplasia to squamous carcinoma in the head and neck region: An epidemiological assessment
47. Direct action of estrogen on sequence of progression of human preneoplastic breast disease
48. Natural history of cervical neoplasia: Defining progression and its consequence
49. Multi-step evolution of lung cancer
50. Barrett's esophagus: The metaplasia-dysplasia-carcinoma sequence: Morphological aspects
51. Predicting cancer development in oral leukoplakia: Ten years of translational research
52. Multiple head and neck tumors: Evidence for a common clonal origin
53. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck
54. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment
55. Prediction of recurrence by microsatellite analysis in head and neck cancer
56. Head and neck cancer
57. Changing patterns of failure in advanced head and neck cancer
58. Cancer statistics, 1996
59. The use of exfoliative cell samples to map clonal genetic alterations in the oral epithelium of high-risk patients
60. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: Molecular evidence of incomplete resection
61. Squamous cell carcinoma of the oral tongue: An analysis of prognostic factors
62. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck
63. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy
64. Phenotypic and genotypic disparity in premalignant lesions: Of calm water and crocodiles
65. 13-cis-retinoic acid in the treatment of oral leukoplakia
66. Second esophageal tumors in patients with head and neck squamous cell carcinoma: An assessment of clonal relationships
67. Local tumor recurrence or emergence of a new primary lesion? A molecular analysis
68. Risk of preneoplastic and neoplastic events in operated oral leukoplakias
69. DNA content as a prognostic marker in patients with oral leukoplakia
70. Molecular markers of the risk of oral cancer
71. The current status of gene therapy
72. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer